Effect of daptomycin on prothrombin time and the requirement for outlier exclusion in International Sensitivity Index calibration of thromboplastin [3]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 9, 2007, Pages 1975-1976

  Van Den Besselaar, A M H P ^a   Tripodi, A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DAPTOMYCIN; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN;

ANTIBIOTIC SENSITIVITY; ANTICOAGULANT THERAPY; BLOOD CLOTTING TEST; CELL MEMBRANE TRANSPORT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; PRIORITY JOURNAL; PROTHROMBIN TIME;

CALIBRATION; DAPTOMYCIN; HUMANS; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN;

EID: 34548106988     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02679.x     Document Type: Letter

References (5)

1. Kanafani ZA, Corey GR. Daptomycin: A rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 2007; 5: 177-84.
2. Tripodi A, Chantarangkul V, Negri B, Mannucci PM. International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost 1998; 79: 439-43.
3. Chantarangkul V, van den Besselaar AMHP, Witteveen E, Tripodi A. International collaborative study for the calibration of a proposed international standard for thromboplastin, rabbit, plain. J Thromb Haemost 2006; 4: 1339-45.
4. WHO Expert Committee on Biological Standardization. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. WHO Tech Rep Ser 1999; 889: 64-93.
5. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46: 31-3.